| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers P > Headlines for Pharmexa A/S > News item |
Pharmexa starts treatment in phase 2 trial of HER-2 Protein AutoVac with QS-21
New York, Dec. 15 - Pharmexa A/S said the first patients have begun treatment in its phase 2 trial of HER-2 Protein AutoVac in combination with the adjuvant QS-21 for breast cancer.
Participants will receive four initial immunizations over six weeks with 1.25 mg of HER-2 Protein AutoVac formulated with Alhydrogel adjuvant and mixed with QS-21 adjuvant, followed by booster immunizations every four weeks for up to 26 weeks.
The trial is being carried at 10 to 15 cancer research centers in Poland, Romania and Russia.
Each center will recruit 40 patients with active HER-2 positive breast cancer.
Pharmexa is a Hørsholm, Denmark, biotechnology company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.